Benzodiazepines may increase risk of CAP, mortality
Benzodiazepines, which have been associated with an increased incidence of infections in the critically ill, also may increase the risk of community-acquired pneumonia, according to a recent report published in Thorax.
Benzodiazepines, which have been associated with an increased incidence of infections in the critically ill, also may increase the risk of community-acquired pneumonia (CAP) and mortality following pneumonia, according to a recent report published in Thorax.
In a case-control study of approximately 29,700 controls and 5,000 patients with CAP from a UK patient database (2001-2002), researchers investigated the association between benzodiazepines and CAP occurrence as well as the impact of the drugs on mortality in the patients with CAP.
Eneanya Obiora, Division of Epidemiology and Public Health, University of Nottingham, UK, and colleagues found that use of benzodiazepines was associated with an increased risk of pneumonia (OR=1.54; 95% CI, 1.42–1.67). Diazepam, lorazepam, and temazepam were all associated with an increased incidence of CAP. In addition, this drug class was associated with increased 30-day (HR=1.22; 95% CI, 1.06–1.39) and long-term mortality (HR=1.32; 95% CI, 1.19–1.47) in patients who had a prior diagnosis of CAP.
The authors of the study suggested that further research is needed to determine the immune safety profile of benzodiazepines.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
